Thrilled to launch season 3 of Power to the Patients! Steven Gourlay, CEO of Actinogen joins Power CEO, Brandon Li, to discuss Actinogen's innovative approach to Alzheimer's treatment. Steven shares his background in clinical trials and drug development, highlighting the potential of the company's lead molecule, Xanamem, a daily pill aimed at reducing brain cortisol levels. Their conversation covers the challenges in Alzheimer's & depression research and the promising early clinical data. Steven sheds insight on the strategic focus on Alzheimer's over depression due to unmet medical needs and the future direction in Alzheimer's research. Brandon and Steven also dive into the regulatory landscape, patient selection criteria, and the broader implications of Actinogen's work in transforming the treatment landscape for neurodegenerative diseases.
Related Podcasts
Subscribe to Power's Newsletter
Stay ahead with a new patient recruitment insight every week.